Skip to main content
SpringerLink
Log in

LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

We studied the role of long intergenic non-protein coding RNA 00,511 (LINC00511) in lung adenocarcinoma (LUAD), with a specific focus on acquired chemoresistance. LINC00511 expression was higher in responders to cisplatin (DDP, another name for cisplantin) than non-responders, in A549/DDP cells than in parental A549 cells and normal human bronchial epithelial cells (16HBE). LINC00511 knockdown decreased the half maximal inhibitory concentration (IC50) value, suppressed A549/DDP cell viability, but induced apoptosis. LINC00511 bound with miR-182 and increased the expression of baculoviral inhibitor of apoptosis protein (IAP) repeat containing 5 (BIRC5). BIRC5 knockdown mimicked the effects of LINC00511 knockdown on the IC50 value, A549/DDP cell viability, and apoptosis. BIRC5 overexpression negated the effects of LINC00511 knockdown on A549/DDP cells. In vivo, LINC00511 knockdown attenuated the tumorigenesis of A549/DDP cells after DDP injection. These results provide a novel LINC00511/miR-182/BIRC5 paradigm to explain the mechanism of acquired DDP resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of Data and Material

Not applicable.

Abbreviations

ceRNA:

Competitive endogenous RNA

ECL:

Enhanced chemiluminescence

EGFR:

Epidermal growth factor receptor

FBS:

Fetal bovine serum

IC50:

Inhibitory concentration

LncRNAs:

Long non-coding RNAs

LUAD:

Lung adenocarcinoma

miRNA:

MicroRNA

PBS:

Phosphate buffer solution

PI:

Propidium iodide

PVDF:

Poly (vinylidene fluoride)

RECIST:

Response evaluation criteria in solid tumors

SPF:

Specific pathogen-free

References

  1. Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7–34.

    Google Scholar 

  2. She, J., Yang, P., Hong, Q., & Bai, C. (2013). Lung cancer in China: Challenges and interventions. Chest, 143, 1117–1126.

    Article  Google Scholar 

  3. Zeng, Z. L., Zhao, G. F., Zhu, H. K., Nie, L., He, L., Liu, J., Li, R., Xiao, S., & Hua, G. (2020). LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis. Cancer Cell International, 20, 350.

    Article  CAS  Google Scholar 

  4. Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000). Lung cancer. Lancet (London, England)., 355, 479–485.

    Article  CAS  Google Scholar 

  5. Wu, K. L., Tsai, M. J., Yang, C. J., Chang, W. A., Hung, J. Y., Yen, C. J., Shen, C. H., Kuo, T. Y., Lee, J. Y., Chou, S. H., Liu, T. C., Chong, I. W., & Huang, M. S. (2015). Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer, 88, 187–194.

    Article  Google Scholar 

  6. Preusser, M., Berghoff, A. S., Koller, R., Zielinski, C. C., Hainfellner, J. A., Liebmann-Reindl, S., Popitsch, N., Geier, C. B., Streubel, B., & Birner, P. (2015). Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. European Journal of Cancer, 51, 1803–1811.

    Article  CAS  Google Scholar 

  7. Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., Murray, B. A., Imielinski, M., Hu, X., Ling, S., Akbani, R., Rosenberg, M., Cibulskis, C., Ramachandran, A., Collisson, E. A., Kwiatkowski, D. J., Meyerson, M. (2016). Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 48, 607–616.

    Article  CAS  Google Scholar 

  8. Cancer Genome Atlas Research Network. (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543–550.

    Article  Google Scholar 

  9. Li, Y., Sheu, C. C., Ye, Y., de Andrade, M., Wang, L., Chang, S. C., Aubry, M. C., Aakre, J. A., Allen, M. S., Chen, F., Cunningham, J. M., Deschamps, C., Jiang, R., Lin, J., Marks, R. S., Pankratz, V. S., Su, L., Li, Y., Sun, Z., … Yang, P. (2010). Genetic variants and risk of lung cancer in never smokers: A genome-wide association study. The lancet Oncology, 11, 321–330.

    Article  CAS  Google Scholar 

  10. Zagryazhskaya, A., Gyuraszova, K., & Zhivotovsky, B. (2015). Cell death in cancer therapy of lung adenocarcinoma. International Journal of Developmental Biology, 59, 119–129.

    Article  CAS  Google Scholar 

  11. Yang, J., Qiu, Q., Qian, X., Yi, J., Jiao, Y., Yu, M., Li, X., Li, J., Mi, C., Zhang, J., Lu, B., Chen, E., Liu, P., & Lu, Y. (2019). Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer. Molecular Cancer, 18, 171.

    Article  CAS  Google Scholar 

  12. Hua, Q., Jin, M., Mi, B., Xu, F., Li, T., Zhao, L., Liu, J., & Huang, G. (2019). LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. Journal of Hematology & Oncology, 12, 91.

    Article  Google Scholar 

  13. Thomson, D. W., & Dinger, M. E. (2016). Endogenous microRNA sponges: Evidence and controversy. Nature Reviews Genetics, 17, 272–283.

    Article  CAS  Google Scholar 

  14. Zhao, Y., Chen, X., Jiang, J., Wan, X., Wang, Y., & Xu, P. (2020). Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis. Biochimica et Biophysica Acta Molecular Basis of Disease, 1866, 165856.

    Article  CAS  Google Scholar 

  15. Wang, X. F., Liang, B., Chen, C., Zeng, D. X., Zhao, Y. X., Su, N., Ning, W. W., Yang, W., Huang, J. A., Gu, N., & Zhu, Y. H. (2020). Long intergenic non-protein coding RNA 511 in cancers. Frontiers in Genetics, 11, 667.

    Article  CAS  Google Scholar 

  16. Huang, X. X., Zhang, Q., Hu, H., Jin, Y., Zeng, A. L., Xia, Y. B., & Xu, L. (2020). A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182–5p. Journal of Cellular Biochemistry, 122, 1009–1020.

    Article  Google Scholar 

  17. Seidl, C., Panzitt, K., Bertsch, A., Brcic, L., Schein, S., Mack, M., Leithner, K., Prinz, F., Olschewski, H., Kornmueller, K., & Hrzenjak, A. (2020). MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Letters, 469, 266–276.

    Article  CAS  Google Scholar 

  18. Ou, D. M., Wu, Y., Liu, J., Lao, X. M., Zhang, S., & Liao, G. Q. (2016). miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting surviving. Oncology Letters, 12, 2531–2537.

    Article  CAS  Google Scholar 

  19. Shen, J., Yin, Q., Chen, L., Zhang, Z., & Li, Y. (2012). Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials, 33, 8613–8624.

    Article  CAS  Google Scholar 

  20. Makovec, T. (2019). Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and Oncology, 53, 148–158.

    Article  CAS  Google Scholar 

  21. Cocetta, V., Ragazzi, E., & Montopoli, M. (2020). Links between cancer metabolism and cisplatin resistance. International Review of Cell and Molecular Biology, 354, 107–164.

    Article  CAS  Google Scholar 

  22. Shen, J. G., Xu, S. N., & Yin, L. G. (2020). LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp. General Physiology and Biophysics, 39, 481–489.

    Article  Google Scholar 

  23. Xiong, X. D., Ren, X. C., Cai, M. Y., Yang, J. W., Liu, X., & Yang, J. M. (2016). Long non-coding RNAs: An emerging powerhouse in the battle between life and death of tumor cells. Drug Resistance Updates, 26, 28–42.

    Article  Google Scholar 

  24. Yuan, Y., Li, E., Zhao, J., Wu, B., Na, Z., Cheng, W., & Jing, H. (2021). Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer. Anti-Cancer Drugs, 32, 178–188.

    Article  CAS  Google Scholar 

  25. Xue, J., & Zhang, F. (2020). LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR-625-5p. Thorac. Cancer., 11, 2570–2579.

    Article  CAS  Google Scholar 

  26. Jiang, L., Xie, X., Bi, R., Ding, F., & Mei, J. (2020). Knockdown of Linc00511 inhibits TGF-beta-induced cell migration and invasion by suppressing epithelial-mesenchymal transition and down-regulating MMPs expression. Biomedicine & Pharmacotherapy, 125, 109049.

    Article  CAS  Google Scholar 

  27. Zhu, F. Y., Zhang, S. R., Wang, L. H., Wu, W. D., & Zhao, H. (2019). LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. European Review for Medical and Pharmacological Sciences, 23, 8377–8390.

    PubMed  Google Scholar 

  28. Xu, T., Yu, Y., Guo, S., He, L., & Mao, Z. (2020). CircPSMC3 suppresses migration and invasion of non-small cell lung cancer cells via mir-182–5p/NME2 axis. Medical Science Monitor, 26, e924134.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Li, X., Yang, B., Ren, H., Xiao, T., Zhang, L., Li, L., Li, M., Wang, X., Zhou, H., & Zhang, W. (2019). Hsa_circ_0002483 inhibited the progression and enhanced the Taxol sensitivity of non-small cell lung cancer by targeting miR-182-5p. Cell Death & Disease, 10, 953.

    Article  CAS  Google Scholar 

  30. Tang, C., Luo, H., Luo, D., Yang, H., & Zhou, X. (2018). Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells. Oncology Reports, 39, 611–618.

    CAS  PubMed  Google Scholar 

  31. Mattheolabakis, G., Ling, D., Ahmad, G., & Amiji, M. (2016). Enhanced anti-tumor efficacy of lipid-modified platinum derivatives in combination with survivin silencing siRNA in resistant non-small cell lung cancer. Pharmaceutical Research, 33, 2943–2953.

    Article  CAS  Google Scholar 

  32. Liu, B., Pan, C. F., Ma, T., Wang, J., Yao, G. L., Wei, K., & Chen, Y. J. (2017). Long non-coding RNA AK001796 contributes to cisplatin resistance of non-small cell lung cancer. Molecular Medicine Reports, 16, 4107–4112.

    Article  CAS  Google Scholar 

  33. Yang, Q., Tang, Y., Tang, C., Cong, H., Wang, X., Shen, X., & Ju, S. (2019). Diminished LINC00173 expression induced miR-182-5p accumulation promotes cell proliferation, migration and apoptosis inhibition via AGER/NF-κB pathway in non-small-cell lung cancer. American Journal of Translational Research, 11, 4248–4262.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by the Cangzhou City Key Research and Development Plan Guidance Project Task Book (183302108).

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, 061000, Hebei, China

    Zhongcheng Zhu, Yufeng Shi & Mingyun Zhang

  2. Return Visit Office, Cangzhou Central Hospital, Cangzhou, 061000, Hebei, China

    Xiaoyi Gong & Jing Li

Authors
  1. Zhongcheng Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yufeng Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoyi Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingyun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZCZ is responsible for the guarantor of integrity of the entire study, study concepts & design, definition of intellectual content, literature research, clinical studies, experimental studies, data analysis; YFS is responsible for the study concepts & design, clinical studies, data acquisition, statistical analysis, manuscript editing; XYG is responsible for the statistical analysis, manuscript editing; JL is responsible for the definition of intellectual content, experimental studies, data acquisition & analysis, manuscript preparation; MYZ is responsible for the definition of intellectual content, clinical studies, experimental studies, manuscript preparation & review. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Zhongcheng Zhu.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethics Approval

The study was approved by the Cangzhou Central Hospital (No.2017–008-01).

Informed Consent

Informed consent was obtained.

Consent for Publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, Z., Shi, Y., Gong, X. et al. LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5. Mol Biotechnol 64, 252–262 (2022). https://doi.org/10.1007/s12033-021-00400-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-021-00400-0

Keywords

Search

Navigation